Pages

Showing posts with label aspirin prevents cancer. Show all posts
Showing posts with label aspirin prevents cancer. Show all posts

Friday, 9 December 2016

'Not enough over-50s' taking aspirin to prevent heart disease

reposted from: http://www.nhs.uk/news/2016/12December/Pages/Not-enough-over-50s-taking-aspirin-to-prevent-heart-disease.aspx
crabsallover highlights, key points, comments / links.

December 1 2016

You shouldn’t take daily aspirin unless a doctor advises you to.

Aspirin can help prevent blood clots.

"Aspirin a day could dramatically cut cancer and heart disease risk … study claims," the Mail Online reports.

U.S. researchers ran a simulation of what might happen if all Americans over 50 years old took aspirin on a daily basis. Their results found that people would live about four months longer on average, adding 900,000 people to the US population by 2036.

More info from NHS.uk.

The study was designed to demonstrate the possible long-term effects of more people taking aspirin to prevent cardiovascular disease.

It should be pointed out that there is an important difference between UK and US guidelines. In the UK low-dose aspirin is usually recommended for people with a history of heart disease or stroke. In the US this advice is extended to people who are at risk of cardiovascular disease but don't have it yet.

We already know that aspirin reduces the risk of heart disease and strokes caused by blood clots (ischaemic stroke). There's some evidence it may reduce some types of cancer. However, aspirin also increases the risk of stroke caused by bleeding (haemorrhagic stroke) and increases the chances of bleeding in the stomach or gut.

So should you be taking low-dose aspirin? Without knowing your individual circumstances it is impossible to provide an accurate response. You need to ask your GP.

Where did the story come from?

The study was carried out by researchers from the University of Southern California and a company called Analysis Group. The authors received no funding for the study.

The study was published in the peer-reviewed journal PLOS One, on an open-access basis so it's free to read online.

The Mail Online reports the study as if the findings about aspirin reducing cardiovascular disease and potentially extending lifespan were new, while they have actually been known for some time.

The report says taking aspirin "would save the US $692 billion in health costs," which seems to be a misunderstanding. Health costs would actually increase, because of people living longer.

However, the researchers assigned a value of $150,000 to each additional year of life lived, which is how they arrived at the $692 billion figure.

What kind of research was this?

This was a "microsimulation" study, which used a modelling system to project possible outcomes under different scenarios, using information from health surveys. This type of modelling can throw up some interesting possibilities, but because it relies on so many assumptions, we have to be cautious about taking the results too literally.

What did the research involve?

Researchers used data from cohort studies to predict average life expectancy, cardiovascular events, cancers, disabilities and healthcare costs for people in the US aged 50 and over. They predicted what would happen with the current numbers of people taking aspirin, then with everyone currently recommended to take aspirin doing so, then with everyone over 50 taking aspirin.

They compared the results of their modelling, to see what effect it would have on average lifespan, the US population, costs and benefits.

Cohort studies providing data included the National Health and Nutrition Examination Survey (NHANES), Health and Retirement Study of Americans, Medical Expenditure Panel Survey and Medicare Current Beneficiary Survey.
The model included an assumption that more people would have gastrointestinal bleeding as a result of taking aspirin. It also modified the results using quality of life measures, so that additional life years were adjusted for quality of life.

What were the basic results?

The researchers found that, if everyone advised by US guidelines to take aspirin did so, the:
  • numbers of people with cardiovascular disease would fall from 487 per 1,000 to 476 per 1,000 (11 fewer cases, 95% confidence interval (CI) -23.2 to -2)
  • numbers with gastrointestinal bleeding would rise from 67 per 1,000 to 83 per 1,000 (16 more cases, 95% CI 3.6 to 30)
  • years of life expectancy at age 51 would rise from 30.2 years to 30.5 years, an additional four months of life (0.28 year, 95% CI 0.08 to 0.5)
  • life expectancy without disability would rise from 22.8 years to 22.9 years, an additional one month of life (0.12 year, 0.03 to 0.23)
The model found no reduction in the numbers of strokes or cancers.

The model shows there could be an additional 900,000 people (CI 300,000 to 1,400,000) alive in the US in 2036, who would otherwise have died.

Using the figure of $150,000 per quality-adjusted life year to represent benefits, the researchers say the value of extra life gained by 2036 would be $692 billion.

How did the researchers interpret the results?

The researchers said: "Expanded use of aspirin by older Americans with elevated risk of cardiovascular disease could generate substantial population health benefits over the next twenty years, and do so very cost-effectively."

Conclusion

This study doesn't really tell us anything we didn't already know. Aspirin has been used for many years to prevent heart attacks and strokes in people with cardiovascular disease. Aspirin's wider use is controversial, because of the potential side effects.

What this study does add is an estimate of what might happen if all people in the US who were advised to take aspirin under US guidelines, actually did so. (The researchers say that 40% of men and 10% of women advised to take aspirin don't take it).

The study assumes that people would get the same benefits as those seen in clinical trials of aspirin. This is unrealistic, because most studies find that people tend to do better in clinical trials than when being treated in the real world.

The average results – showing an additional one month of disability-free life for every 1,000 people – may sound trivial. However, it's important to remember that averages don't work like that in real life. Many people will get no benefit from aspirin, while a smaller group will avoid a heart attack or stroke, and so live many more months or possibly years, as a result of taking aspirin.

If you've already had a heart attack or stroke, or if you have angina or another heart or circulation problem, your doctor has probably prescribed low dose aspirin. There's good evidence that aspirin (or similar drugs, for those who can't take aspirin) can help prevent a second heart attack or stroke.

Find out more information about aspirin.
Analysis by Bazian. Edited by NHS Choices. Follow NHS Choices on Twitter. Join the Healthy Evidence forum.
Analysis by Bazian
Edited by NHS Choices

Links to the headlines

Aspirin a day could dramatically cut cancer and heart disease risk - and even extend lifespan, study claims. Mail Online, November 30 2016

Links to the science

Agus DB, Gaudette E, Goldman DP, Messali A. The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLOS One. Published online November 30 2016

Friday, 22 April 2016

Aspirin can protect against cancer - and treat it.

Crabsallover has covering the aspirin-anti-cancer link since 2011 when Peter Rothwell peer-reviewed research strongly indicated that taking a daily aspirin could prevent cancers.
"Aspirin is already used by millions to reduce the risk of heart attacks and strokes. But the latest research suggests that the drug could also have a major role in treating and preventing cancer. Cheap and safe, it is the nearest we have to a wonder drug, says Jeremy Laurance. So, should we all be taking it?"
 "Dutch researchers reported that a daily aspirin could double the life expectancy of patients with gastro-intestinal cancers"
"In a study presented in Vienna this week [September 2015], Dutch researchers reported that a daily aspirin could double the life expectancy of patients with gastro-intestinal cancers – of the oesophagus, stomach and colon. Among the 14,000 cancer patients studied, regular users of the drug were twice as likely to be alive after four years as those who were not taking it."
"Aspirin can halt the march of any cancer through the body"
"Overall, the research suggests that a daily low dose (75mg) aspirin taken for at least five years in middle age can reduce the risk of developing gastro-intestinal cancers (of the oesophagus, stomach and colon) by around 20 per cent. It also protects against other cancers such as breast, lung and prostate, but the reduction in risk is less pronounced. As a treatment, it may be even more powerful. A review of eight large randomised controlled trials – the gold standard of medical research and stronger evidence than Dr Frouws' “observational” study – involving 25,000 patients taking a low daily dose of aspirin to ward off heart disease – found the drug reduced deaths due to all cancers by more than a fifth (21 per cent)."
 "Aspirin makes the blood less able to carry cancer cells."
"Published in The Lancet in 2011, that review was followed by a second one, published in 2012, of five randomised trials, which found that patients with cancer taking a daily aspirin reduced “distant metastasis” – spread to organs such as the brain, liver and lungs, which is usually terminal – by 30-40 per cent... Peter Rothwell, Professor of neurology at Oxford University and doyen of aspirin researchers, who conducted both reviews, said this was powerful evidence. Aspirin can halt cancer's remorseless march through the body (though it does not prevent local spread). And not just specific cancers but any cancer."
"The drug appears to work by making the platelets, one of the constituents of the blood, less “sticky”. As a cancer grows, cells break off and are carried round the body in the blood by the platelets until deposited in a distant organ, where they form a new tumour. By reducing the platelets' stickiness, aspirin makes it harder for them to carry and distribute the cancer cells."
"Critics, however, urge caution before aspirin is recommended for mass medication. They point out that most of the randomised controlled trials cited as evidence of its benefits were not designed to test its anti-cancer effects. Potential dangers may not be apparent from trials involving different patient populations."
reposted from: http://www.independent.co.uk/life-style/health-and-families/features/aspirin-can-protect-against-cancer-and-treat-it-according-to-new-research-a6676056.html 

Sunday, 6 March 2016

Too soon for 'aspirin doubles cancer survival' claim

In September 2015, several UK newspapers covered research on use of aspirin to enhance cancer survival.

According to the Mail: "Three quarters of people with bowel, stomach or throat cancer were still alive five years later, and aspirin is the 'magic bullet' that should be prescribed as soon as someone is diagnosed."

reposted from:http://www.nhs.uk/news/2015/09September/Pages/too-soon-for-aspirin-doubles-cancer-survival-claim.aspx

US study confirms Peter Rothwell findings that cancers are reduced with daily aspirin

Can aspirin reduce bowel cancer risk? "Taking two aspirin a week could protect against cancer," reports the Daily Telegraph. The Express suggests we should take it daily.

In a large study, researchers found that aspirin use twice or more per week was associated with a 3% reduction in cancer risk. However, when analysed by cancer type, there was only one significant link – for bowel cancer – with a 19% risk reduction for aspirin use.

The research seems to confirm some of Oxfords Peter Rothwells' findings.

reposted from: http://www.nhs.uk/news/2016/03March/Pages/can-aspirin-reduce-risk-of-bowel-cancer.aspx

Friday, 15 August 2014

Daily aspirin 'reduces cancer risk', study finds

Jack Cuzick has been reported here for his trials on aspirin.

reposted from: http://www.nhs.uk/news/2014/08August/Pages/Daily-aspirin-reduces-cancer-risk-study-finds.aspx
crabsallover highlights, key points, comments / links.

Taking aspirin every day could cut your risk of developing cancer, report BBC News and The Daily Telegraph among other news outlets, after the publication of a large-scale review of the evidence.
People aged between 50 and 65 who take aspirin every day for 10 years could cut their risk of bowel cancer by 30% and cancers of the throat and stomach by 25%, according to the study published in the Annals of Oncology.
Aspirin is an antiplatelet, which means it reduces the risk of clots forming in your blood. Platelets may also protect cancer cells in the body, and it has been suggested aspirin's effect on them may hinder this process. However, the exact mechanism is not well understood and more research is needed.
Taking aspirin every day comes with a serious health warning as it can cause serious side effects such as ulcers and bleeding from the stomach, particularly in elderly people.
However, the researchers argue the benefits of taking the drug need to be balanced against the harms. 
While the findings of this study show promise, it is not clear whether the methods used in compiling it were systematic, so the results may not be entirely reliable.
Anyone thinking of taking aspirin for prevention should talk to their GP first.

Who may not be able to take aspirin?

Before taking aspirin, including for pain relief, you should talk to your GP or pharmacist if:
  • you are pregnant, trying for a baby or breastfeeding
  • you have a blood disorder
  • you have ever had a stomach ulcer
  • you suffer from asthma
  • you have liver or kidney problems
  • you have high blood pressure
  • you have haemophilia or any other bleeding disorder
  • you have had an unusual or allergic-type reaction to any medicine
  • you are taking other medicines
Aspirin should also not be given to children under 16 years of age

Where did the story come from?

The study was carried out by researchers from a number of institutions across Europe and the US, including Queen Mary University of London.
It was funded by Cancer Research UK, the British Heart Foundation and the American Cancer Society. The study was published in the peer-reviewed medical journal Annals of Oncology.
Several of the study's authors are consultants to, or have other connections with, pharmaceutical companies with an interest in antiplatelet agents such as aspirin.
As might be expected with cancer-related news, the research was widely covered in the press. Most of the coverage was uncritical, although most stories warned of the side effects of taking aspirin.

What kind of research was this?

This was a review of evidence on the association between aspirin and incidence of deaths from cancer and cardiovascular disease, and potential harmful side effects.
It is not clear whether this was a systematic review, where the evidence is rigorously appraised for its quality and risk of bias. The researchers did not carry out a meta-analysis of the results of studies included, but compiled their own estimates.
The authors say regular aspirin is known to reduce the incidence of cardiovascular disease both in the general population and in high-risk groups, although it is currently only recommended for those at high risk.
However, an increasing body of evidence suggests it may also have a role in cancer prevention. Aspirin is also associated with a risk of bleeding and peptic ulcers. The researchers argue the benefits of taking the drug need to be balanced against the harms.

What did the research involve?

Researchers gathered evidence on the effects of aspirin on cancer risk and cancer deaths from systematic reviews published between 2009 and 2012, as well as from some individual studies on specific cancers. Further systematic reviews undertaken by some of the researchers were not included, but were discussed at the "evidence review meeting".
It is not clear how these studies were chosen or whether further studies on the topic were excluded and, if so, what criteria were used to decide which studies to include or exclude.
Evidence for aspirin's effect on cardiovascular disease was taken from one large meta-analysis. The authors based their calculations of the effect aspirin would have on cardiovascular disease by using UK rates from 1998 for cardiovascular-related incidents and deaths, which they adjusted to take account of downward trends in recent years in both the UK and the US.
The researchers used a detailed unpublished analysis of the harmful effects of aspirin.
They calculated the overall benefits and harms for taking aspirin for 10 years, starting at ages 50, 55, 60 and 65, separately for men and women. They made several assumptions in their analysis:
  • the cardiovascular benefit and adverse effects only occur during active treatment (the 10-year period)
  • the protection against cancer begins three years after initiating aspirin and continues for an additional five years after stopping aspirin
  • the protection against cancer mortality begins five years after starting aspirin use and lasts for an additional 10 years after treatment is stopped
  • the protective effects are seen only in colorectal, oesophageal, gastric, breast, prostate and lung cancers

What were the basic results?

The researchers calculated that for average-risk individuals aged 50 to 65 taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period, and an overall 4% relative reduction in all deaths over a 20-year period.
Below are their calculations of the effect of aspirin in reducing the risk of cancers and cardiovascular events, giving what the researchers say are "conservative" estimates:
  • colorectal (bowel) cancer – 30% reduction in incidence and 35% reduction in deaths
  • oesophageal cancer – 25% reduction in incidence and 45% reduction in deaths
  • gastric cancer – 25% reduction in incidence and 30% reduction in deaths
  • lung cancer – no reduction in incidence, 10% reduction in deaths
  • prostate cancer – 5% reduction in incidence, 10% reduction in deaths
  • breast cancer – 5% reduction in incidence, no reduction in deaths
  • heart attack – 18% reduction in incidence, 5% reduction in deaths
  • stroke – 5% reduction in incidence, 21% increase in deaths
Their calculations on the risk of side effects from taking aspirin are:
  • major (extracranial) bleeding – 70% increase in incidence
  • gastric bleeding – 70% increase in deaths
  • peptic ulcer – 70% increase in deaths
They also say the effects are not apparent until at least three years after starting aspirin, and some benefits may be sustained for several years after stopping.
They found no difference between low and high doses of aspirin in terms of health benefits, although there were no studies that did direct comparisons.

How did the researchers interpret the results?

The researchers say once aspirin's effect on cancer risk and mortality is taken into account, the benefits of taking aspirin outweigh the risks.
They calculate that to get any benefit, people need to start taking a daily dose of between 75mg and 325mg for a minimum of five years. Longer use is likely to have greater benefits, they say.
Further research is needed to determine the optimum dose for taking aspirin and duration of use, and to identify those at increased risk of bleeding.
In an accompanying press release, lead author Professor Jack Cuzick of Queen Mary University of London said: "It has long been known that aspirin – one of the cheapest and most common drugs on the market – can protect against certain types of cancer.
"But until our study, where we analysed all the available evidence, it was unclear whether the pros of taking aspirin outweighed the cons.
"Whilst there are some serious side effects that can't be ignored, taking aspirin daily looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity, and will probably be much easier to implement."

Conclusion

While the findings on aspirin and cancer show promise, it is not clear that the results are reliable from the methods reportedly used to compile this review.
This is because it included studies of varying design and quality, with much of the evidence coming from observational studies, which, while useful, cannot be totally relied on to test the effectiveness of healthcare interventions.
It's not clear how the studies included in the review were chosen and whether others on the same topic were excluded. It is also not clear whether or not this was a systematic review, where studies are rigorously appraised for their quality, and criteria are established for their inclusion.
Aspirin can cause major side effects such as peptic ulcers and bleeding from the stomach, particularly in older people. It's important to consult with your GP before deciding to take aspirin regularly. 

Analysis by Bazian. Edited by NHS Choices. Follow Behind the Headlines on Twitter. Join the Healthy Evidence forum.



Wednesday, 1 August 2012

Asprin's 'double hit' on bowel cancer

Ref: Asprin's 'double hit' on bowel cancer

reposted from:
crabsallover highlights, key points, comments / links.


Asprin's 'double hit' on bowel cancer
31 May 2012
Aspirin kills cancer cells by controlling two key processes that influence energy use in cells and could explain how aspirin can prevent bowel cancer.

The research is published in Gastroenterology.

Cancer Research UK-funded scientists have found that aspirin switches off mTOR (mammalian Target Of Rapamycin) (wikipedia), a protein that is overactive in bowel cancer cells. 

mTOR plays a part in allowing cancer cells to produce excess proteins causing them to grow faster than they should.

At the same time, aspirin activates another protein, AMPK, which switches on pathways that generate energy but halts other processes in the cell that need energy, including mTOR.

In showing this ‘double hit’, the scientists, based at the University of Edinburgh and Dundee, have unveiled an important mechanism by which aspirin causes cancer cells to destroy themselves.

Researcher Dr Farhat Din, a Cancer Research UK clinician scientist fellow at the University of Edinburgh, said: “There is growing evidence showing that aspirin protects against cancer, but how it brings this about is the subject of much active research. Our new work shows, for the first time, that aspirin is acting on two master regulators of energy in bowel cancer cells and has given us a real insight to the disease.”

mTOR acts in the cell as a central hub that monitors levels of nutrients. By studying cancer cell lines, mice and samples from patients, the researchers were able to show that aspirin was blocking mTOR by measuring levels of proteins that it controls.

There is a growing body of evidence that aspirin can help prevent several cancers, though we know that long term aspirin use can cause harm in some high risk groups.

The scientists’ ultimate aim is to identify targets in the processes involved in cell energy balance in order to develop new drugs that are even better and safer than aspirin at preventing bowel and other cancers.

Dr Din added: “Drugs that target mTOR have been hampered by the cancer’s ability to find alternative ways of using the same pathway, leaving these drugs useless. Using aspirin as a template, we hope to be able to develop drugs that target several parts of the same pathway, enabling us to get around this resistance.”

Professor Nic Jones, Cancer Research UK’s chief scientist, said: “This fascinating research provides an invaluable insight into how aspirin is working in bowel cancer cells. It builds on this team’s earlier work that was the first to demonstrate that aspirin worked to prevent bowel cancer. Cancer Research UK is funding trials and research to find out more about the role aspirin could have in preventing cancer.

“We recommend that anyone considering taking aspirin for cancer prevention should discuss doing so with their GP.”

Source: CRUK